Immunosuppressants drugs living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 all comers	COVID-19 mild to moderate

	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate
Immunosuppressants drugs
anakinra	SAVE-MORE		CORIMUNO-ANA-1
anti-interleukin-6
sarilumab	CORIMUNO-SARI-1 ...
sarilumab high dose (400mg)		sarilumab phase 2 high dose
sarilumab low dose (200mg)		sarimulab phase 2 low dose
tocilizumab	EMPACTA NCT04412772 ... Tsai RECOVERY Declercq J ... RCT-TCZ-COVID-19 SAM-COVID-19 Soin AS ... NCT04577534 ... EU-CTR2020-001375-32 ... Martinez-Sanz EU-CTR2020-001748-24 ... HNF Hospital Tocilizumab multidisciplinary team NCT04479358 ... Rutgers NCT04434717 ... Dongsheng Wang Colaneri	TOCOVID BACC Bay Tocilizumab Trial	Capra
canakinumab	Sheng ...
janus kinase (JAK) inhibitor
baricitinib	COV-BARRIER ACTT-2 ...	RECOVERY	Rodriguez-Garcia Cantini
tofacitinib	STOP-COVID ...		Murugesan
lenzilumab			LIVE-AIR ...